Which has stronger valuation & earnings, ORIC or XENE?

Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A Xenon Pharmaceuticals N/A N/A -$345.91M -$4.74 N/A

Is ORIC or XENE more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Xenon Pharmaceuticals N/A -43.98% -41.72%

Does the media favor ORIC or XENE?

In the previous week, Xenon Pharmaceuticals had 17 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 23 mentions for Xenon Pharmaceuticals and 6 mentions for Oric Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.39 beat Oric Pharmaceuticals' score of 1.17 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 18 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ORIC or PTCT?

In the previous week, PTC Therapeutics had 10 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 16 mentions for PTC Therapeutics and 6 mentions for Oric Pharmaceuticals. PTC Therapeutics' average media sentiment score of 1.23 beat Oric Pharmaceuticals' score of 1.17 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORIC or CRSP?

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 6 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.17 beat CRISPR Therapeutics' score of 0.77 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LGND or ORIC?

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 5 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.35 beat Oric Pharmaceuticals' score of 1.17 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORIC or GRFS?

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 3 mentions for Grifols. Oric Pharmaceuticals' average media sentiment score of 1.17 beat Grifols' score of 0.88 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oric Pharmaceuticals (ORIC) Competitors

$13.24 -0.50 (-3.64%)

As of 08/28/2026 04:00 PM Eastern

Compare

ORIC vs. XENE, PTCT, CRSP, LGND, and GRFS

Should you buy Oric Pharmaceuticals stock or one of its competitors? Oric Pharmaceuticals's main competitors and comparable companies include Xenon Pharmaceuticals (XENE), PTC Therapeutics (PTCT), CRISPR Therapeutics (CRSP), Ligand Pharmaceuticals (LGND), and Grifols (GRFS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oric Pharmaceuticals compare to Xenon Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Oric Pharmaceuticals currently has a consensus price target of $19.45, indicating a potential upside of 46.94%. Xenon Pharmaceuticals has a consensus price target of $77.13, indicating a potential upside of 28.58%. Given Oric Pharmaceuticals' higher possible upside, equities analysts clearly believe Oric Pharmaceuticals is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Oric Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Oric Pharmaceuticals' return on equity of -35.35% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A

In the previous week, Xenon Pharmaceuticals had 17 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 23 mentions for Xenon Pharmaceuticals and 6 mentions for Oric Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.39 beat Oric Pharmaceuticals' score of 1.17 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	18 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oric Pharmaceuticals beats Xenon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to PTC Therapeutics?

Oric Pharmaceuticals (NASDAQ:ORIC) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Oric Pharmaceuticals has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. Oric Pharmaceuticals' return on equity of -35.35% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Oric Pharmaceuticals currently has a consensus price target of $19.45, indicating a potential upside of 46.94%. PTC Therapeutics has a consensus price target of $98.55, indicating a potential upside of 40.60%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Oric Pharmaceuticals is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

In the previous week, PTC Therapeutics had 10 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 16 mentions for PTC Therapeutics and 6 mentions for Oric Pharmaceuticals. PTC Therapeutics' average media sentiment score of 1.23 beat Oric Pharmaceuticals' score of 1.17 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PTC Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. PTC Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
PTC Therapeutics	$1.73B	3.38	$682.64M	-$0.58	N/A

Oric Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Summary

Oric Pharmaceuticals beats PTC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to CRISPR Therapeutics?

Oric Pharmaceuticals (NASDAQ:ORIC) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Oric Pharmaceuticals has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Oric Pharmaceuticals presently has a consensus price target of $19.45, suggesting a potential upside of 46.94%. CRISPR Therapeutics has a consensus price target of $68.06, suggesting a potential upside of 17.91%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Oric Pharmaceuticals is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 6 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.17 beat CRISPR Therapeutics' score of 0.77 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market.

Oric Pharmaceuticals has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
CRISPR Therapeutics	$11M	507.37	-$581.60M	-$4.76	N/A

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Oric Pharmaceuticals beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Oric Pharmaceuticals (NASDAQ:ORIC) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 5 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.35 beat Oric Pharmaceuticals' score of 1.17 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	20.86	$124.45M	$9.35	30.00
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Ligand Pharmaceuticals presently has a consensus target price of $335.75, indicating a potential upside of 19.70%. Oric Pharmaceuticals has a consensus target price of $19.45, indicating a potential upside of 46.94%. Given Oric Pharmaceuticals' higher possible upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Ligand Pharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Oric Pharmaceuticals' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Summary

Ligand Pharmaceuticals beats Oric Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Grifols?

Oric Pharmaceuticals (NASDAQ:ORIC) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 3 mentions for Grifols. Oric Pharmaceuticals' average media sentiment score of 1.17 beat Grifols' score of 0.88 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Grifols has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oric Pharmaceuticals currently has a consensus target price of $19.45, suggesting a potential upside of 46.94%. Grifols has a consensus target price of $10.00, suggesting a potential upside of 30.04%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Oric Pharmaceuticals is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Grifols has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Grifols	$8.51B	0.61	$454.82M	$0.19	40.47

Grifols has a net margin of 5.54% compared to Oric Pharmaceuticals' net margin of 0.00%. Grifols' return on equity of 6.21% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Grifols	5.54%	6.21%	2.39%

Summary

Oric Pharmaceuticals beats Grifols on 8 of the 15 factors compared between the two stocks.

Get Oric Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORIC vs. The Competition

Export

Metric	Oric Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.37B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-9.81	11.62	273.16	25.45
Price / Sales	N/A	1,295.89	605.01	76.63
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	3.60	16.53	12.98	6.14
Net Income	-$129.47M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-6.76%	-0.31%	0.13%	-0.80%
1 Month Performance	13.75%	9.80%	7.08%	4.13%
1 Year Performance	29.42%	55.66%	24.67%	15.17%

Oric Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORIC Oric Pharmaceuticals	3.1125 of 5 stars	$13.24 -3.6%	$19.45 +46.9%	+29.4%	$1.37B	N/A	N/A	80	News Coverage Positive News Insider Trade
XENE Xenon Pharmaceuticals	2.5641 of 5 stars	$60.56 -0.3%	$77.13 +27.4%	+55.0%	$5.87B	$7.50M	N/A	210	News Coverage Positive News
PTCT PTC Therapeutics	3.7793 of 5 stars	$71.06 +1.8%	$98.55 +38.7%	+42.1%	$5.83B	$1.73B	N/A	1,410	News Coverage Positive News Insider Trade
CRSP CRISPR Therapeutics	2.3114 of 5 stars	$57.08 -4.1%	$68.06 +19.2%	+11.4%	$5.75B	$3.51M	N/A	460	Analyst Forecast
LGND Ligand Pharmaceuticals	4.1101 of 5 stars	$280.18 -2.1%	$335.75 +19.8%	+73.5%	$5.71B	$290.54M	29.97	80	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORIC) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. XENE, PTCT, CRSP, LGND, and GRFS

How does Oric Pharmaceuticals compare to Xenon Pharmaceuticals?

Summary

How does Oric Pharmaceuticals compare to PTC Therapeutics?

Summary

How does Oric Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Oric Pharmaceuticals compare to Ligand Pharmaceuticals?

Summary

How does Oric Pharmaceuticals compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. XENE, PTCT, CRSP, LGND, and GRFS

How does Oric Pharmaceuticals compare to Xenon Pharmaceuticals?

Do analysts prefer ORIC or XENE?

Which has more volatility and risk, ORIC or XENE?

Is ORIC or XENE more profitable?

Do insiders and institutionals believe in ORIC or XENE?

Which has stronger valuation & earnings, ORIC or XENE?

Does the media favor ORIC or XENE?

Summary

How does Oric Pharmaceuticals compare to PTC Therapeutics?

Is ORIC or PTCT more profitable?

Do analysts recommend ORIC or PTCT?

Does the media prefer ORIC or PTCT?

Do institutionals & insiders believe in ORIC or PTCT?

Which has stronger earnings and valuation, ORIC or PTCT?

Which has more risk and volatility, ORIC or PTCT?

Summary

How does Oric Pharmaceuticals compare to CRISPR Therapeutics?

Is ORIC or CRSP more profitable?

Do analysts rate ORIC or CRSP?

Does the media favor ORIC or CRSP?

Which has more volatility and risk, ORIC or CRSP?

Which has stronger earnings & valuation, ORIC or CRSP?

Do institutionals and insiders hold more shares of ORIC or CRSP?

Summary

How does Oric Pharmaceuticals compare to Ligand Pharmaceuticals?

Do insiders and institutionals believe in LGND or ORIC?

Does the media prefer LGND or ORIC?

Which has higher valuation & earnings, LGND or ORIC?

Do analysts recommend LGND or ORIC?

Which has more risk and volatility, LGND or ORIC?

Is LGND or ORIC more profitable?

Summary

How does Oric Pharmaceuticals compare to Grifols?

Does the media favor ORIC or GRFS?

Which has more volatility & risk, ORIC or GRFS?

Do institutionals and insiders have more ownership in ORIC or GRFS?

Do analysts prefer ORIC or GRFS?

Which has stronger earnings & valuation, ORIC or GRFS?

Is ORIC or GRFS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools